Skip to content
Peptigraph home

PERFORMA: Pemvidutide Phase 3 trial (NCT07795164)

A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Registry record checked

At a glance

Phase
Phase 3
Status
Recruiting
Enrolment
1,800
estimated
Start
30 Jul 2026 (actual)
Primary completion
Dec 2028 (estimated)
Sponsor
Altimmune, Inc.
Design

Arms and doses

NCT07795164 study arms
ArmTypeInterventionsDescription
Pemvidutide 1.8 mgExperimentalDrug: PemvidutideNot stated
Pemvidutide 2.4 mgExperimentalDrug: PemvidutideNot stated
PlaceboPlacebo comparatorOther: PlaceboNot stated
Endpoints

Primary endpoint

NCT07795164 primary outcomes
MeasureTime frame
Clinical Outcome EventBaseline through end of study (approximately Month 60)
Histological Response: MASH resolutionBaseline through Week 52
Histological Response: Fibrosis improvementBaseline through Week 52
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT07795164 secondary outcomes
MeasureTime frame
Histologic Response: Proportion of subjects achieving both MASH resolution (according to NASH CRN classification) without worsening of fibrosis and ≥ 1 stage improvement in liver fibrosis without worsening of MASHBaseline through Week 52
HistoIndex qFibrosis: Proportion of subjects with at least a 1 stage improvement in qFibrosisBaseline through Week 52
Anthropometric parameters: Relative (%) change from baseline in body weight (kg)Baseline through End of Study (approximately Month 60)
Anthropometric parameters: Relative (%) change from baseline in body mass index (BMI; kg/m2)Baseline through End of Study (approximately Month 60)
Anthropometric parameters: Relative (%) change from baseline in waist circumference (cm)Baseline through End of Study (approximately Month 60)
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in alanine aminotransferase (ALT; U/L)Baseline through End of Study (approximately Month 60)
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in enhanced liver fibrosis (ELF) scoreBaseline through End of Study (approximately Month 60)
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Relative (%) change from baseline in vibration controlled transient elastography (VCTE; kPa) by FibroscanBaseline through End of Study (approximately Month 60)
HRQoL: Change from baseline in core symptoms of MASH on the NASH-CHECK questionnaire.Baseline through End of Study (approximately Month 60)
HRQoL: Change from baseline in Short-form 36 (SF-36) summary scores.Baseline through End of Study (approximately Month 60)
HRQoL: Change from baseline in Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) domain scores.Baseline through End of Study (approximately Month 60)
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.